



CANDESARTAN + INDAPAMIDE Film-coated Tablets

An innovative Fixed Dose
Combination (FDC)
supported by guidelines*

- It is indicated for replacement therapy of essential hypertension in adult patients whose blood pressure is controlled by a combination of candesartan and indapamide administered simultaneously in the same doses as in the combination.

Designed for substitution
therapy

Available strengths: 32+5mg, 32+2.5mg, 16+5mg, 16+2.5mg,
8+5mg, 8+2.5mg

Improved patient
compliance

Both substances already used in standard therapy of hypertension

- Candesartan (and its combination) is a widely used hypertension drug, with approximately 4.7 billion tablets sold (MAT Q2 2023) in the EU27+UK.
- Hydrochlorothiazide (HCTZ), a diuretic, has seen a decline in doctor prescriptions due to perceived side effects.
- To replace the older diuretic HCTZ in a well-known combination product with candesartan, the newer diuretic indapamide is being introduced.

* Williams, B (ESC Chairperson) et. al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension 36(10):p 1953-2041, October 2018. | DOI: 10.1097/HJH.0000000000001940

Regulatory pathway

- Legal basis: Article 10b fixed dose combination


Development status



- Prototype development is currently underway
- Our clinical strategy involves a combination of:
- Pharmacokinetic (PK) studies
- Analysis of co-prescription data
- Review of relevant literature information

Partnership options

- The product is available for out-licensing in select European markets
- The product is also available for licensing outside of Europe

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

 Zentiva Group a.s.
U Kabelovny529/16, 102 00 Prague 10, Czech Republic

 Zent2U@zentiva.com
 +420 267243231

 www.Zent2U.com

ZENTIVA